bluuebunny/crossref_metadata_2025_split huggingface dataset:
From Bach to Helloween: ‘Teutonic’ stereotypes in the history of popular music and heavy metal
Authors: Herbst Jan-Peter 
Published: February 2020

Abstract
Throughout the centuries, German popular music has caused various foreign reactions from admiration to outright rejection. Sometimes, international audiences perceived it as too ‘Teutonic’; other times, this was exactly the reason for its appeal. This article traces ‘Teutonic’ features in 400 years of German popular music history, seeking to identify the emergence and development of ‘Teutonic’ stereotypes as well as their perception inland and abroad. The metal discourse was analysed based on a corpus of nearly 200,000 pages from magazines such as the British Kerrang! and the German Metal Hammer, Rock Hard and Deaf Forever. Stereotypes such as perfectionism, precision and rigidity seem to stem from historical roots, yet their projection onto ‘Teutonic metal’ is over-simplified and often out of context. History suggests that German metal bands were most successful when they exaggerated Germanness. Occasionally, bands became successful because their German features made them sound unique, even though they did not promote their heritage proactively. More often, though, bands that were unintentionally perceived as typically German were less appealing to a foreign audience. In the magazines, discussion of Teutonic attributes almost vanished in the twenty-first century. Global production practices needing to conform to international expectations of ever faster, tighter and heavier records likely made metal artists around the world adopt qualities that previously defined ‘Teutonic music’. It will therefore be interesting to see if or how German stereotypes in metal music will live on.
Book Reviews
Authors: Hazle Dawn , Herbst Jan-Peter , Samoylova Pavla 
Published: February 2020

AbstractWhen the Uncertainty Principle Goes to 11: Or How to Explain Quantum Physics with Heavy Metal, Philip Moriarty (2018)Dallas, TX: BenBella Books Ltd., 352 pp.,ISBN 978-1-94464-852-7, p/bk, $17.95Gender Inequality in Metal Music Production, Pauwke Berkers and Julian Schaap (2018)Bingley: Emerald Publishing, 176 pp.,ISBN 978-1-78714-675-4, p/bk, £40.00Gender Inequality in Metal Music Production, Pauwke Berkers and Julian Shaap (2018)Bingley: Emerald Publishing Limited, 149 pp.,ISBN 978-1-78714-675-4, p/bk, £40.00
Planning for the Future: The Role of Nurse Practitioners and Physician Assistants in Survivorship Care
Authors: McCabe Mary S. , Pickard Todd Alan 
Published: February 2020

Overview: The number of cancer survivors in the United States now approaches 12 million individuals, with an estimated 7.2% of the general population aged 18 years or older reporting a previous cancer diagnosis. These figures highlight a number of questions about the care of survivors—how patients at risk for a known set of health problems should be followed, by whom, and for how long. At the same time that oncologists are developing strategies to provide services to this growing population, there are economic and systems challenges that have relevance to the previous questions, including a predicted national shortage of physicians to provide oncology services. Nurse practitioners (NPs) and physician assistants (PAs) have been identified as members of the health care team who can help reduce the oncology supply and demand gap in a number of ways. The ASCO Study of Collaborative Practice Arrangements (SCPA) in 2011 concluded that oncology patients were aware and satisfied when their care was provided by NPs and PAs; there was an increase in productivity in practices that utilized NPs and PAs; utilizing the full scope of practice of NPs and PAs was financially advantageous; and, physicians, NPs, and PAs are highly satisfied with their collaborative practices. Increasingly, the oncology and health policy literature contains evidence supporting innovative provider models. There is still much work to be done to move beyond pilot data to establish the true value of these models.
Refining the Role of Radiation Therapy in Pediatric Hodgkin Lymphoma
Authors: Hudson Melissa M. , Constine Louis S. 
Published: February 2020

Overview: The role of radiation therapy in the treatment of pediatric Hodgkin lymphoma has continued to be refined, motivated by the desire to avoid disruption to normal tissue development and function and secondary carcinogenesis. Such progress has occurred in tandem with modifications of the multiagent chemotherapy regimens that have been used in place of or in combination with low-dose involved-field radiation that are also associated with dose-related risks of cardiopulmonary and gonadal dysfunction and leukemogenesis. Consequently, treatment strategies for young patients, who have an excellent prognosis of long-term survival, utilizes a risk-adapted approach that provides optimal efficacy for disease control whereas limiting toxicity associated with both radiation and chemotherapy. Because of the differences in age-related developmental status and gender-related sensitivity to chemotherapy and radiation toxicity, no single treatment approach is ideal for all pediatric patients. This manuscript summarizes results from published clinical trials with the goal of defining optimal treatment strategies for children and adolescents with Hodgkin lymphoma in regards to the use of radiation therapy.
A Myriad of Symptoms: New Approaches to Optimizing Palliative Care of Patients with Advanced Pancreatic Cancer
Authors: Wiebe Lauren A. 
Published: February 2020

Overview: Patients with advanced pancreatic cancer (APC) require early and frequent palliative interventions to achieve optimal quality of life for the duration of illness. Evidence-based supportive treatments exist to maximize quality of life for any patient, whether receiving chemotherapy or not. This article provides a comprehensive review of symptoms with current treatment recommendations and directions for future development. Celiac plexus neurolysis improves pain in the majority of patients with APC and should be moved earlier in the analgesic paradigm. Malignant bowel obstruction can be palliated quickly with optimal management via gastric decompression, octreotide, parenteral opioids, and standing antiemetics. Recommendations are provided for best treatment of malignant gastroparesis, gastric outlet obstruction, and chemotherapy-induced nausea and vomiting in this population. Malignant ascites can be treated initially with diuretics and sodium-restriction in patients with an exudative process; however, an indwelling catheter is recommended for patients with recurrent ascites, particularly because of carcinomatosis or a refractory process. With exocrine insufficiency contributing to weight loss, pancreatic enzyme replacement is essential to improve nourishment in the majority of patients. Presently, megestrol acetate is the only U.S. Food and Drug Administration (FDA)-approved therapy for the anorexia-cachexia syndrome, although future developments are promising. Finally, patients with advanced pancreatic cancer should be screened and treated early for depression as a common comorbid diagnosis. Early palliative care consultation also helps address the existential and psychosocial concerns of patients facing death from pancreatic cancer in a holistic manner.
Considerations and Controversies in the Management of Older Patients with Advanced Cancer
Authors: Mohile Supriya Gupta , Klepin Heidi D. , Rao Arati V. 
Published: February 2020

Overview: The incidence of cancer increases with age. Oncologists need to be adept at assessing physiologic and functional capacity in older patients in order to provide safe and efficacious cancer treatment. Assessment of underlying health status is especially important for older patients with advanced cancer, for whom the benefits of treatment may be low and the toxicity of treatment high. The comprehensive geriatric assessment (CGA) is the criterion standard for evaluation of the older patient. The combined data from the CGA can be used to stratify patients into categories to better predict risk for chemotherapy toxicity as well as overall outcomes. The CGA can also be used to identify and follow-up on possible functional consequences from treatment. A variety of screening tools might be useful in the oncology practice setting to identify patients who may benefit from further testing and intervention. In this chapter, we discuss how the principles of geriatrics can help improve the clinical care of older adults with advanced cancer. Specifically, we discuss assessing tolerance for treatment, options for chemotherapy scheduling and dosing for older patients with advanced cancer, and management of under-recognized symptoms in older patients with cancer.
Buoyancy: A Model for Self-Reflection about Stress and Burnout in Oncology Providers
Authors: Fisch Michael J. 
Published: February 2020

Overview: Burnout is a prevalent syndrome among oncology providers marked by exhaustion, a sense of ineffectiveness, and depersonalization. This syndrome can have enormous influence on patient care as well as the provider's career fulfillment and personal and family well-being. A buoyancy model is proposed as a method to take stock of key parameters that may contribute to happiness and resiliency. Self-monitoring of personal buoyancy parameters may help oncology providers prevent burnout.
Advanced Biliary Tract Cancers
Authors: Goff Laura Williams , Berlin Jordan D. 
Published: February 2020

Overview: Single-agent management of metastatic biliary tract cancers with 5-fluorouracil (5-FU) or gemcitabine has shown limited efficacy, although 5-FU has been shown to be more effective than best supportive care alone. An analysis of phase II trials has suggested that platinums enhanced the efficacy of single-agent fluoropyrimidines. In a phase III randomized trial comparing single-agent gemcitabine with gemcitabine plus cisplatin, the gemcitabine/cisplatin combination significantly improved median overall survival (OS) and progression-free survival (PFS), which established a new option for standard of care. However, the future of cancer medicine lies in newer, targeted agents. In the management of biliary tract cancers, preliminary evidence with epidermal growth factor receptor inhibitors has already demonstrated activity. This article reviews systemic therapies for metastatic biliary tract cancers as they relate to current and emerging standards of care.
Driving Evidence-Based Standardization of Care within a Framework of Personalized Medicine
Authors: Brufsky Adam , Lokay Kathleen , McDonald Melissa 
Published: February 2020

Overview: Cancer care in the United States faces a number of key challenges today that are causing payers, referring physicians, and patients alike to question the value of the care, in terms of both outcomes and costs. New technologies in the form of pharmaceuticals and biologics, prognostic tests, and new radiation therapy tools and techniques offer the promise of improved outcomes, but their cost-effectiveness is often unclear. Oncologists themselves are caught in the middle, as they are the prescribers of such technologies and the entity billing for such services but have only limited ability to influence the pricing models for these services. Finally, as oncology care becomes more complex because of increased understanding of the pathogenesis of the many subtypes of cancer, the community-based oncologist who cares for patients with all cancer subtypes is confronted with maintaining an up-to-date knowledge base that is expanding rapidly. Although no single solution for these issues exists in oncology today, the experience at the University of Pittsburgh Medical Center has demonstrated that a clinical pathways program can reduce unwarranted variability in both treatment and outcomes, drive adherence to evidence-based medicine, and, in the process, reduce the growth rate in the total costs of cancer care.
Clinical and Imaging Surveillance Following Breast Cancer Diagnosis
Authors: Flowers Chris I. , Mooney Blaise P. , Drukteinis Jennifer S. 
Published: February 2020

Overview: Breast cancer is the most common malignancy affecting women worldwide. Women have a 1 in 8 lifetime risk of breast cancer. Breast conservation therapy (BCT) is the most common method of definitive treatment. Patients who previously have had to undergo mastectomy may be now eligible for BCT or a multitude of options for reconstruction, either immediate or delayed. Surveillance imaging after a breast cancer diagnosis is important because there is an increased risk of recurrence developing in patients, and early detection has been shown to improve survival. There is currently no consensus on a protocol for imaging the postoperative breast. In patients who have undergone mastectomy, detection of recurrence has mostly been via clinical symptoms and physical exam, often at a later stage. New imaging modalities, such as magnetic resonance imaging (MRI), ultrasound (US), and positron emission mammography (PEM) are changing the way we image the postsurgical breast. MRI, coupled with physical exam and mammography, approaches 100% sensitivity and high specificity for the identification of recurrent disease. We present a review of major academic institutions' imaging protocols and discuss the advantages of including MRI in traditional mammographic and clinical exams.
Combination Therapies Building on the Efficacy of CTLA4 and BRAF Inhibitors for Metastatic Melanoma
Authors: Ribas Antoni 
Published: February 2020

Overview: The demonstration of improved survival with the anti-CTLA4 antibody ipilimumab and the BRAF inhibitor vemurafenib in patients with metastatic melanoma is arguably the most significant advance in the treatment for these patients in the last 30 years. However, the majority of patients will either not experience response, or will experience response and then progression, when receiving these therapies, so additional treatment options are required. Since these agents have been developed with a refined understanding of their mechanism of action and mechanisms leading to resistance are being elucidated, then combination therapies building on these single-agent therapies can be designed rationally. Such combinations are being tested both preclinically and in the clinic, and provide a strong promise to improve on the current treatment approaches for patients with metastatic melanoma.
Transplant in Chronic Lymphocytic Leukemia: To Do It or Not and If So, When and How?
Authors: Gribben John G. 
Published: February 2020

Overview: Most patients with chronic lymphocytic leukemia (CLL) have an indolent clinical course, but the disease remains incurable with standard therapy and the prognosis is dismal for those patients with disease refractory to available treatment options. The only potentially curative treatment is allogeneic hematopoietic stem cell transplantation (SCT), but since CLL is a disease of elderly patients, few patients are candidates for myeloablative allogeneic SCT. Although autologous SCT is feasible and has low treatment-related mortality, it is not curative. The widespread adoption of reduced-intensity conditioning (RIC) allogeneic SCT has made this approach applicable to the elderly patient population with CLL. This approach relies on the documented graft-versus-leukemia (GVL) effect and is strong in CLL. Steps to further decrease the morbidity and mortality of the RIC SCT and in particular to reduce the incidence of chronic extensive graft-versus-host disease (GVHD) remain a major focus. Many potential treatments are available for CLL, and appropriate patient selection and SCT timing remain controversial and the focus of ongoing clinical trials. The use of SCT must always be weighed against the risk of the underlying disease, particularly in a setting where improvements in treatment are leading to improved outcome. The major challenge remains how to identify which patients with CLL merit this approach and where in the treatment course this treatment can be applied optimally.
The Creation of the International Thymic Malignancies Interest Group as a Model for Rare Diseases
Authors: Detterbeck Frank C. 
Published: February 2020

Overview: Similar to other orphan diseases, little progress has been made in the past decades in thymic malignancies. A determination to make a difference, despite the challenges facing a rare disease, led to the formation of the International Thymic Malignancies Interest Group (ITMIG) in 2010. This organization has brought together the majority of those focused on the management of thymic malignancies and has built a foundation for scientific collaboration, including consistent use of terms, an international database, and multidisciplinary engagement of clinicians and researchers from around the world. ITMIG has embarked on the development of novel approaches to research particularly suited to a rare condition. ITMIG has gained substantial recognition for the rapid progress that has been made and serves as a model for the advancement of knowledge in a rare disease.
Prognostic, Predictive, and Surrogate Factors for Individualizing Treatment for Men with Castration-Resistant Prostate Cancer
Authors: Bitting Rhonda L. , Armstrong Andrew J. 
Published: February 2020

Overview: With the surge in therapeutic options for castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision making, highlighting the need for biomarkers that can identify appropriate patients for specific treatments and accurately assess disease response. Here we discuss existing and potential prognostic, predictive, and surrogate biomarkers in CRPC.
Varying Lymphadenectomies for Gastric Adenocarcinoma in the East Compared with the West: Effect on Outcomes
Authors: Schmidt Benjamin , Yoon Sam S. 
Published: February 2020

Overview: There are notable differences in surgical approaches to gastric adenocarcinoma throughout the world, particularly in terms of the extent of lymphadenectomy (LAD). In high-incidence countries such as Japan and South Korea, more extensive (e.g., D2) lymphadenectomies are standard, and these surgeries are generally done by experienced surgeons with low morbidity and mortality. In countries such as the United States, where the incidence of gastric adenocarcinoma is 10-fold lower, the majority of patients are treated at nonreferral centers with less extensive (e.g., D1 or D0) lymphadenectomy. There is little disagreement among gastric cancer (GC) experts that the minimum lymphadenectomy that should be performed for gastric adenocarcinoma should be at least a D1 lymphadenectomy, and many of these experts recommend a D2 lymphadenectomy. More extensive lymphadenectomies provide better staging of patient disease and likely reduce locoregional recurrence rates. Two large, prospective randomized trials performed in the United Kingdom and the Netherlands in the 1990s failed to demonstrate a survival benefit of D2 over D1 lymphadenectomy, but these trials have been criticized for inadequate surgical training and high surgical morbidity and mortality rates (10% to 13%) in the D2 group. More recent studies have demonstrated that Western surgeons can be trained to perform D2 lymphadenectomies on Western patients with low morbidity and mortality. The 15-year follow-up of the Netherlands trial now demonstrates an improved disease-specific survival and locoregional recurrence in the D2 group. Retrospective analyses and one prospective, randomized trial suggest that there may be a survival benefit to more extensive lymphadenectomies when performed safely, but this assertion requires further validation.
Stage III Colon Cancer: What Works, What Doesn't and Why, and What's Next
Authors: André Thierry , O'Neil Bert H. , Meyerhardt Jeffrey A. 
Published: February 2020

Overview: Adjuvant treatment for patients with stage III colon cancer, one of the most common malignancies, is an important issue in oncology. The use of adjuvant chemotherapy in this setting has undoubtedly improved prognosis. This article describes the development of adjuvant therapy and progress in the past decade as well as failures in multiple agents that have demonstrated efficacy in the metastatic setting. Finally, the current clinical trials will be reviewed, as well as complementary therapies including diet and exercise for survivors of colorectal cancer.
Minimally Invasive Surgery of Rectal Cancer: Current Evidence and Options
Authors: Trakarnsanga Atthaphorn , Weiser Martin R. 
Published: February 2020

Overview: Minimally invasive surgery (MIS) of colorectal cancer has become more popular in the past two decades. Laparoscopic colectomy has been accepted as an alternative standard approach in colon cancer, with comparable oncologic outcomes and several better short-term outcomes compared to open surgery. Unlike the treatment for colon cancer, however, the minimally invasive approach in rectal cancer has not been established. In this article, we summarize the current status of MIS for rectal cancer and explore the various technical options.
New Frontiers in Mucositis
Authors: Peterson Douglas E. , Keefe Dorothy M. , Sonis Stephen T. 
Published: February 2020

Overview: Mucositis is among the most debilitating side effects of radiotherapy, chemotherapy, and targeted anticancer therapy. Research continues to escalate regarding key issues such as etiopathology, incidence and severity across different mucosae, relationships between mucosal and nonmucosal toxicities, and risk factors. This approach is being translated into enhanced management strategies. Recent technology advances provide an important foundation for this continuum. For example, evolution of applied genomics is fostering development of new algorithms to rapidly screen genomewide single-nucleotide polymorphisms (SNPs) for patient-associated risk prediction. This modeling will permit individual tailoring of the most effective, least toxic treatment in the future. The evolution of novel cancer therapeutics is changing the mucositis toxicity profile. These agents can be associated with unique mechanisms of mucosal damage. Additional research is needed to optimally manage toxicity caused by agents such as mammalian target of rapamycin (mTOR) inhibitors and tyrosine kinase inhibitors, without reducing antitumor effect. There has similarly been heightened attention across the health professions regarding clinical practice guidelines for mucositis management in the years following the first published guidelines in 2004. New opportunities exist to more effectively interface this collective guideline portfolio by capitalizing upon novel technologies such as an Internet-based Wiki platform. Substantive progress thus continues across many domains associated with mucosal injury in oncology patients. In addition to enhancing oncology patient care, these advances are being integrated into high-impact educational and scientific venues including the National Cancer Institute Physician Data Query (PDQ) portfolio as well as a new Gordon Research Conference on mucosal health and disease scheduled for June 2013.